The FDA has approved an autoinjector formulation of Zilbrysq, a complement inhibitor for the treatment of generalized myasthenia gravis.
While the national burden of pediatric-onset multiple sclerosis is stable, regional incidence and disability rates are increasing in some states.
Starting disease-modifying therapy within 90 days of a neuromyelitis optica spectrum disorder attack may improve long-term disability recovery.
The MSToronto2026 conference will feature new research on multiple sclerosis diagnosis, biomarkers, and emerging therapeutic ...
Machine learning models utilizing cardiovascular and lifestyle factors can accurately predict the 10-year risk of dementia in both men and women.
The prevalence of unruptured intracranial aneurysms has risen in recent years, particularly among older adults and women.
Higher levels of physical activity are associated with slower cognitive and motor progression among people with mild-to-moderate Parkinson disease.
Dexmedetomidine administration is rising in opioid use disorder-related hospitalizations due to medetomidine appearing in illicit fentanyl.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results